# A Phase 2 Study to Evaluate the Efficacy and Safety of Live SK08 Powder in Adult Patients with Active Mild to Moderate Ulcerative Colitis

> **NCT06725017** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Guangzhou Zhiyi Biotechnology Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Ulcerative Colitis (UC)

## Interventions

- **DRUG:** Live SK08 powder
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06725017
- **Lead sponsor:** Guangzhou Zhiyi Biotechnology Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2027-07-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06725017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06725017, "A Phase 2 Study to Evaluate the Efficacy and Safety of Live SK08 Powder in Adult Patients with Active Mild to Moderate Ulcerative Colitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06725017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*